high5immunology.tv | IBD | UEG Week 2022

Therapeutic concepts: Discussions

REACT-2

UEGweek 2022

Treat-to-target still alive?

S. Schreiber, A. Dignass, M. Allez, A. Armuzzi, D. Laharie, M. Fantini

LADI

UEGweek 2022

What is the best dose of adalimumab in CD?

A. Dignass, S. Schreiber, F. Gomollon, J. Lindsay, G. Mantzaris, G. Rogler

LOVE-CD

UEGweek 2022

The benefit of early intervention in CD

A. Dignass, S. Schreiber, F. Gomollon, J. Lindsay, G. Mantzaris, G. Rogler

STARDUST

UEGweek 2022

Treat-to-target with ustekinumab - why didn't it work?

A. Dignass, S. Schreiber, F. Gomollon, J. Lindsay, G. Mantzaris, G. Rogler

LADI

UEGweek 2022

Personalized therapy - de-escalation strategies

A. Dignass, M. Allez, A. Armuzzi, M. Fantini

VEGA, REACT-2

UEGweek 2022

What is new in anti-TNFα therapy?

A. Dignass, S. Schreiber, A. Moschen, P. Eder, P. Irving, F. Magro, S. Danese

UEGweek 2022

Is IL-23 the super target?

S. Schreiber, A. Dignass, M. Allez, A. Armuzzi, D. Laharie, M. Fantini

Therapeutic concepts ENG

UEGweek 2022

T reg - a new therapeutic target in IBD?

Piotr Eder, MD

VEGA

UEGweek 2022

VEGA - the story continues

David Laharie, MD

STARDUST

UEGweek 2022

Pharmacokinetics of ustekinumab in the STARDUST trial

Fernando Magro, MD

VEGA

UEGweek 2022

Combination therapy: week 38 efficacy and safety data…

Massimo Fantini, MD

UEGweek 2022

Explosion of new drugs

Fernando Gomollon, MD

UEGweek 2022

Thinking out of the box - co-medication of the elderly

Gerhard Rogler, MD

IDEAL

UEGweek 2022

Oral anti-integrin therapy in IBD - new data, new…

Piotr Eder, MD

UEGweek 2022

You can still treat severe biofailure in CD

Gerassimos Mantzaris

UEGweek 2022

No matter what you use - treat early!

Gerassimos Mantzaris, MD

UEGweek 2022

Small molecules in crohn's disease

Silvio Danese, MD

UEGweek 2022

Treating the patient as a whole

Iris Dotan, MD

UEGweek 2022

Postoperative monitoring matters!

Gerhard Rogler, MD

REACT-2

UEGweek 2022

Treat-to-target strategy is superior to conventional…

Massimo Fantini, MD

VEGA

UEGweek 2022

Longterm potential benefit of a combIo therapy

Matthieu Allez, MD

LATTICE-UC

UEGweek 2022

TYK2 Deucravacitinib in ulcerative colitis

Stefan Schreiber, MD

LOVE-CD

UEGweek 2022

Once more a shocking message: be aware of steroids!

Gerassimos Mantzaris

REACT-2

UEGweek 2022

Enhanced treatment algorithm for the management of CD

James Lindsay, MD

UEGweek 2022

Anti-IL-23 monoclonal antibodies: is it better to…

Matthieu Allez, MD

Therapeutic concepts Multi Language

UEGweek 2022

Thinking out of the box - Einfluss der…

Gerhard Rogler, MD

VEGA

UEGweek 2022

VEGA - l'histoire continue

David Laharie, MD

VEGA

UEGweek 2022

Terapia di combinazione: efficacia e sicurezza a 38…

Massimo Fantini, MD

UEGweek 2022

Anticorps anti-IL-23: est-il préferabble de cibler…

Matthieu Allez

UEGweek 2022

T reg - nowy cel terapeutyczny w IBD?

Piotr Eder, MD

UEGweek 2022

Small molecules nel morbo di crohn

Silvio Danese, MD

UEGweek 2022

Treating the patient as a whole

Iris Dotan, MD

REACT-2

UEGweek 2022

Una strategia “Treat-to-target” è superiore rispetto…

Massimo Fantini, MD

LOVE-CD

UEGweek 2022

Ακόμα ένα πολύ ανησυχητικό μήνυμα: Πρόσεχε τα…

Gerassimos Mantzaris, MD

VEGA

UEGweek 2022

Les résultats à long terme d'une combIothérapie

Matthieu Allez, MD

LATTICE-UC

UEGweek 2022

TYK2 Deucravacitinib bei Colitis ulcerosa

Stefan Schreiber, MD

IDEAL

UEGweek 2022

Doustna terapia antyintegrynowa - nowe dane, nowe…

Piotr Eder, MD

UEGweek 2022

Explosión de nuevos fármacos

Fernando Gomollon, MD

UEGweek 2022

Μπορείς ακόμη να θεραπεύσεις ανθεκτική στα βιολογικά…

Gerassimos Mantzaris, MD

UEGweek 2022

Ανεξάρτητα του τι θα χορηγήσεις χορήγησέ το έγκαιρα!

Gerassimos Mantzaris

UEGweek 2022

Was tun nach der Operation?

Gerhard Rogler, MD

Targeting efficacy: Discussions

LUCENT-1, LUCENT-2

UEGweek 2022

Update on IL-23 inhibition in UC

A. Dignass, S. Schreiber, A. Moschen, P. Eder, P. Irving, F. Magro

ELEVATE UC 52, ELEVATE UC 12, TRUE NORTH

UEGweek 2022

S1P receptor modulators

A. Dignass, S. Schreiber, A. Moschen, P. Eder, P. Irving, F. Magro

U-ACHIEVE

UEGweek 2022

Update on JAK inhibition in UC

A. Dignass, S. Schreiber, A. Moschen, P. Eder, P. Irving, F. Magro, S. Danese

U-EXCEL

UEGweek 2022

1st JAK inhibitor in CD - a game changer?

A. Dignass, S. Schreiber, A. Moschen, P. Eder, P. Irving, F. Magro, S. Danese

Targeting efficacy ENG

ELEVATE UC 52 & 12

UEGweek 2022

Estrasimod in moderate to severe active UC

James Lindsay, MD

U‑ACHIEVE

UEGweek 2022

Final efficacy and safety results from Upadacitinib 52…

Massimo Fantini, MD

U-ACHIEVE

UEGweek 2022

Upadacitinib maintenance therapy - final results from…

Peter Irving, MD

UEGweek 2022

Risankizumab in refractory CD patients

David Laharie, MD

U-EXCEL

UEGweek 2022

Upadacitinib - induction therapy in CD

Stefan Schreiber, MD

TRUE NORTH

UEGweek 2022

Ozanimod works in young and old UC patient

Peter Irving, MD

U-EXCEL

UEGweek 2022

The 1st JAKi in CD

James Lindsay, MD

VEGA, LUCENT-1, LUCENT-2

UEGweek 2022

VEGA & LUCENT studies

Silvio Danese, MD

UEGweek 2022

Persistance on therapy and real-world clinical…

Massimo Fantini, MD

UEGweek 2022

The era of small molecules

Iris Dotan, MD

LUCENT-1, LUCENT-2

UEGweek 2022

Histological response and remission induced by…

Fernando Magro, MD

QUASAR, LUCENT-1, LUCENT-2, FORTIFY

UEGweek 2022

Selective IL-23 blockade

Axel Dignass, MD

U-ACHIEVE

UEGweek 2022

JAK-inhibition

Axel Dignass, MD

Targeting efficacy Multi Language

VEGA, LUCENT-1, LUCENT-2

UEGweek 2022

VEGA & LUCENT studi clinici

Silvio Danese, MD

U-ACHIEVE

UEGweek 2022

JAK-Inhibition

Axel Dignass, MD

UEGweek 2022

The area of small molecules

Iris Dotan, MD

UEGweek 2022

Risankizumab dans la maladie de Crohn réfractaire

David Laharie, MD

U-EXCEL

UEGweek 2022

Upadacitinib - Induktionsdaten bei CD

Stefan Schreiber, MD

QUASAR, LUCENT-1, LUCENT-2, FORTIFY

UEGweek 2022

Selective IL-23 Blockade

Axel Dignass, MD

U‑ACHIEVE

UEGweek 2022

Risultati finali di efficacia e sicurezza a 52…

Massimo Fantini, MD

UEGweek 2022

Persistenza in terapia ed efficaci clinica di…

Massimo Fantini, MD

Targeting safety: Discussions

OCTAVE

UEGweek 2022

Updated safety data on JAK inhibitors

A. Dignass, M. Allez, A. Armuzzi, M. Fantini

UEGweek 2022

Treating the elderly - closer surveillance and the…

A. Dignass, S. Schreiber, F. Gomollon, J. Lindsay, G. Mantzaris, G. Rogler

Treatment Goals: Discussions

U-ACHIEVE/U-ACCOMPLISH, LUCENT, CONFIDE

UEGweek 2022

Urgency - putting the focus on an important endpoint!

A. Dignass, S. Schreiber, F. Gomollon, J. Lindsay, G. Mantzaris, G. Rogler

UK IBD BioResource database

UEGweek 2022

Steroid effects as treatment goals: quality of life and…

A. Schreiber, A. Dignass, M. Allez, A. Armuzzi, D. Laharie, M. Fantini

Treatment Goals ENG

LUCENT-1, LUCENT-2

UEGweek 2022

Urgency matters!

Peter Irving, MD

SELECTION

UEGweek 2022

Filgotinib is efficacious in inducing and maintaining…

Fernando Magro, MD

CONFIDE

UEGweek 2022

New endpoints in IBD

Axel Dignass, MD

UEGweek 2022

Patient reported outcomes in IBD

Axel Dignass, MD

Treatment Goals Multi Language

UEGweek 2022

Patienten gerichtete Endpunkte bei CED

Axel Dignass, MD

CONFIDE

UEGweek 2022

Neue Studienendpunkte in IBD

Axel Dignass, MD

Diagnostics and Prediction ENG

UEGweek 2022

Whats's the origin of Crohn's genetics ? The history of…

Stefan Schreiber, MD

SEXEII, BUTTERFLY

UEGweek 2022

Explosion of Spanish contributions

Fernando Gomollon, MD

Diagnostics and Prediction Multi Language

UEGweek 2022

Explosión de las comunicaciones españolas

Fernando Gomollon, MD

UEGweek 2022

Wo kommt die Crohn-Genetik her? Die Historie der IL-23…

Stefan Schreiber, MD

Varia ENG

LADI, LUCENT-1, LUCENT-2

UEGweek 2022

Personalised therapy in IBD

Axel Dignass, MD

Varia Multi Language

LADI, LUCENT-1, LUCENT-2

UEGweek 2022

Individualisierte Therapie bei CED

Axel Dignass, MD